Join Growin Stock Community!

Bio-rad laboratories, inc.BIO-B.US Overview

US StockHealthcare
(No presentation for BIO-B)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

BIO-B AI Insights

BIO-B Overall Performance

BIO-B AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

BIO-B Recent Performance

-

Bio-rad laboratories, inc.

0.05%

Avg of Sector

-0.31%

S&P500

BIO-B PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

BIO-B Key Information

BIO-B Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

BIO-B Profile

Bio-Rad Laboratories, Inc. manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company operates through Life Science and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes. It focuses on selected segments of the life sciences market in proteomics, genomics, biopharmaceutical production, cellular biology, and food safety. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology researchers, food producers, and food testing laboratories. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, test kits, and specialized quality controls for clinical laboratories in the diagnostics market. This segment offers reagents, instruments, and software, which address specific niches within the in vitro diagnostics test market. It sells its products to reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, and transfusion laboratories. In addition, the company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.

Price of BIO-B

BIO-B FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

BIO-B Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
28.15
PE Ratio (TTM)
-
Forward PE
23.54
PS Ratio (TTM)
-
PB Ratio
-
Price-to-FCF
19.37
METRIC
VALUE
vs. INDUSTRY
Gross Margin
51.87%
Net Margin
29.42%
Revenue Growth (YoY)
0.65%
Profit Growth (YoY)
-2.86%
3-Year Revenue Growth
-1.72%
3-Year Profit Growth
-4.56%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
28.15
PE Ratio (TTM)
-
Forward PE
23.54
PS Ratio (TTM)
-
PB Ratio
-
Price-to-FCF
19.37
Gross Margin
51.87%
Net Margin
29.42%
Revenue Growth (YoY)
0.65%
Profit Growth (YoY)
-2.86%
3-Year Revenue Growth
-1.72%
3-Year Profit Growth
-4.56%

  • When is BIO-B's latest earnings report released?

    The most recent financial report for Bio-rad laboratories, inc. (BIO-B) covers the period of 2025Q4 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating BIO-B's short-term business performance and financial health. For the latest updates on BIO-B's earnings releases, visit this page regularly.

  • Where does BIO-B fall in the P/E River chart?

    According to historical valuation range analysis, Bio-rad laboratories, inc. (BIO-B)'s current price-to-earnings (P/E) ratio is 2.84, placing it in the Value zone on the P/E River chart. This level indicates that the market's expectations for future earnings are already reflected in the share price, with the valuation currently leaning conservative. Investors are advised to further examine the company's fundamentals and its position in the industry cycle to validate whether the valuation is justified.

  • What is the operating profit of BIO-B?

    According to the latest financial report, Bio-rad laboratories, inc. (BIO-B) reported an Operating Profit of 61.9M with an Operating Margin of 8.93% this period, representing a growth of 6.12% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is BIO-B's revenue growth?

    In the latest financial report, Bio-rad laboratories, inc. (BIO-B) announced revenue of 693.2M, with a Year-Over-Year growth rate of 3.85%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much debt does BIO-B have?

    As of the end of the reporting period, Bio-rad laboratories, inc. (BIO-B) had total debt of 1.53B, with a debt ratio of 0.14. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does BIO-B have?

    At the end of the period, Bio-rad laboratories, inc. (BIO-B) held Total Cash and Cash Equivalents of 531.8M, accounting for 0.05 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does BIO-B go with three margins increasing?

    In the latest report, Bio-rad laboratories, inc. (BIO-B) achieved the “three margins increasing” benchmark, with a gross margin of 49.8%%, operating margin of 8.93%%, and net margin of 103.87%%. This demonstrates improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess BIO-B's profit trajectory and future growth potential.

  • Is BIO-B's EPS continuing to grow?

    According to the past four quarterly reports, Bio-rad laboratories, inc. (BIO-B)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at 26.69. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of BIO-B?

    Bio-rad laboratories, inc. (BIO-B)'s Free Cash Flow (FCF) for the period is 119.1M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 46.59% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of BIO-B?

    The latest valuation data shows Bio-rad laboratories, inc. (BIO-B) has a Price-To-Earnings (PE) ratio of 2.84 and a Price/Earnings-To-Growth (PEG) ratio of -0.01. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.